Ondine Short Long Term Debt Total from 2010 to 2024

OBI Stock   7.75  0.25  3.12%   
Ondine Biomedical's Short and Long Term Debt Total is decreasing over the years with very volatile fluctuation. Short and Long Term Debt Total is expected to dwindle to about 514 K. During the period from 2010 to 2024 Ondine Biomedical Short and Long Term Debt Total annual values regression line had geometric mean of  4,523,269 and mean square error of 103.3 T. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2010-12-31
Previous Quarter
541 K
Current Value
514 K
Quarterly Volatility
9.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ondine Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ondine Biomedical's main balance sheet or income statement drivers, such as Other Operating Expenses of 11.8 M, Total Operating Expenses of 11.2 M or Income Tax Expense of 89.3 K, as well as many indicators such as . Ondine financial statements analysis is a perfect complement when working with Ondine Biomedical Valuation or Volatility modules.
  
This module can also supplement various Ondine Biomedical Technical models . Check out the analysis of Ondine Biomedical Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Ondine Stock

Ondine Biomedical financial ratios help investors to determine whether Ondine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ondine with respect to the benefits of owning Ondine Biomedical security.